Afamitresgene autoleucel as an effective T-cell therapy for synovial sarcoma and liposarcoma
1. Overall response rate to afami-cel in both groups was 37%. 2. The majority of adverse-events were moderate in nature ...
Tag: chimeric antigen receptor (CAR) T-cell therapy
KTE-X19 may induce remission in patients with relapsed or refractory B-cell lymphoblastic leukemia
1. 71% patients achieved complete remission or complete remission with incomplete recovery following KTE-X19 infusion. 2. The majority of adverse ...
Quick Take: T-Cell Receptor Gene Therapy for Human Papillomavirus–Associated Epithelial Cancers: A First-in-Human, Phase I/II Study
Genetically engineered T-cell therapies, such as chimeric antigen receptor T-cells (CAR T-cells), have been approved for the treatment of hematologic ...
2 Minute Medicine Rewind August 19, 2019
Pregnancy duration and endometrial cancer risk: nationwide cohort study Full-term pregnancies are strongly associated with a reduced risk of endometrial ...
#VisualAbstract: Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
1. bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA) proteins, was shown to achieve ...
Anti-BCMA CAR T-cell therapy shows promise in patients with relapsed or refractory multiple myeloma
1. bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA) proteins, was shown to achieve ...